Renal Amyloidosis and Glomerular Diseases with Monoclonal Immunoglobulin Deposition

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 322-334

  Ronco, Pierre M ^a   Aucouturier, Pierre ^b   Moulin, Bruno ^c  

^a SAN BORTOLO HOSPITAL   (Italy)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649925150     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00026-5     Document Type: Chapter

References (52)

1. Glenner GG Amyloid deposits and amyloidosis: The beta-fibrilloses. N Engl J Med 1980, 302:1283-1292.
2. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005, 12:1-4.
3. Merlini G, Bellotti V Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583-596.
4. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002, 346:1786-1791.
5. Westermark G, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature. Amyloid 2002, 9:197-200.
6. Merlini G, Bellotti V Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583-596.
7. Eulitz M, Weiss DT, Solomon A Immunoglobulin heavy-chain-associated amyloidosis. Proc Natl Acad Sci USA 1990, 87:6542-6546.
8. Stevens FJ Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 2000, 7:200-211.
9. Enqvist S, Sletten K, Stevens FJ, et al. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. PLoS ONE 2007, 2:e981.
10. L germ line gene use and clonal plasma cell burden. Blood 2001, 98:714-720.
11. Keeling J, Teng J, Herrera GA AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004, 84:1322-1338.
12. Kyle RA, Gertz MA Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995, 32:45-59.
13. Kyle RA, Greipp PR Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983, 58:665-683.
14. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005, 51:878-881.
15. Wechalekar AD, Lachmann HJ, Goodman HJ, et al. AL amyloidosis associated with IgM paraproteinemia: Clinical profile and treatment outcome. Blood 2008, 112:4009-4016.
16. Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: A French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008, 87:99-109.
17. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003, 122:78-84.
18. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005, 79:319-328.
19. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336:1202-1207.
20. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998, 91:3662-3670.
21. Dember LM, Sanchorawala V, Seldin DC, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001, 134:746-753.
22. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004, 140:85-93.
23. Leung N, Dispenzieri A, Fervenza FC, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 2005, 46:270-277.
24. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103:2936-2938.
25. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357:1083-1093.
26. Sanchorawala V Light-chain (AL) amyloidosis: Diagnosis and treatment. Clin J Am Soc Nephrol 2006, 1:1331-1341.
27. Bollée G, Guery B, Joly D, et al. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol 2008, 3:375-381.
28. Gertz MA, Kyle RA, O'Fallon WM Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med 1992, 152:2245-2250.
29. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371.
30. Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007, 356:2349-2360.
31. Dode C, Pecheux C, Cazeneuve C, et al. Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet 2000, 92:241-246.
32. Randall RE, Williamson WC, Mullinax F, et al. Manifestations of systemic light chain deposition. Am J Med 1976, 60:293-299.
33. Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light (heavy)-chain deposition disease: From molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006, 1:1342-1350.
34. Khurana R, Gillespie JR, Talapatra A, et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 2001, 40:3525-3535.
35. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol 2001, 12:1482-1492.
36. H1. J Am Soc Nephrol 1999, 10:519-528.
37. Keeling J, Herrera GA An in vitro model of light chain deposition disease. Kidney Int 2009, 75:634-645.
38. Kambham N, Markowitz GS, Appel GB, et al. Heavy chain deposition disease: The disease spectrum. Am J Kidney Dis 1999, 33:954-962.
39. Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors. Am J Kidney Dis 2003, 42:1154-1163.
40. Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004, 65:642-648.
41. Hassoun H, Flombaum C, D'Agati VD, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008, 42:405-412.
42. Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008, 23:2052-2057.
43. Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004, 43:147-153.
44. Korbet SM, Schwartz MM, Lewis EJ Current concepts in renal pathology. The fibrillary glomerulopathies. Am J Kidney Dis 1994, 23:751-765.
45. Fogo A, Qureshi N, Horn RG Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 1993, 22:367-377.
46. Alpers CE Immunotactoid (microtubular) glomerulopathy: An entity distinct from fibrillary glomerulonephritis. Am J Kidney Dis 1992, 19:185-191.
47. Bridoux F, Hugue V, Coldefy O, et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002, 62:1764-1775.
48. Rosenstock JL, Markowitz GS, Valeri AM, et al. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int 2003, 63:1450-1461.
49. Collins M, Navaneethan SD, Chung M, et al. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis 2008, 52:1158-1162.
50. Czarnecki PG, Lager DJ, Leung N, et al. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int 2009, 75:420-427.
51. Audard V, Georges B, Vanhille P, et al. Renal lesions associated with IgM-secreting monoclonal proliferations: Revisiting the disease spectrum. Clin J Am Soc Nephrol 2008, 3:1339-1349.
52. Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009, 20:2055-2064.